Press releases
- AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
- AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
- AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
- AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
- AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
- AbCellera Announces Resignation of Board Member
- AbCellera to Present at Upcoming Investor Conferences in March
- AbCellera Reports Full Year 2023 Business Results
- AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
More ▼
Key statistics
On Friday, Abcellera Biologics Inc (8QQ:FRA) closed at 3.63, 0.86% above its 52-week low of 3.60, set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.63 |
---|---|
High | 3.63 |
Low | 3.63 |
Bid | -- |
Offer | -- |
Previous close | 3.66 |
Average volume | 3.48k |
---|---|
Shares outstanding | 292.78m |
Free float | 210.50m |
P/E (TTM) | -- |
Market cap | 1.14bn USD |
EPS (TTM) | -0.5062 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 14:44 BST.
More ▼